Home » Publications » Published 2021 »
Knott CS, Heffernan K, Nikitas FS, Shukla U, Starkie-Camejo H. 812P Demographics and survival outcomes in patients with advanced or recurrent endometrial cancer (EC) following platinum-based doublet (PBD) in the English real-world (RW) setting. Ann Oncol. 2021; 32(5):S766-S767. https://www.annalsofoncology.org/article/S0923-7534(21)03483-9/fulltext
Abstract:
Background
Patients with advanced/recurrent EC following disease progression on or after a PBD therapy have a poor prognosis. This descriptive, noninterventional, retrospective cohort study reports on English patient characteristics and survival outcomes, specifically in a population with advanced/recurrent EC that has progressed on or after a first-line (1L) PBD therapy.
Methods
Routine population-level data, from Public Health England’s National Cancer Registration and Analysis Service (NCRAS), was used for this study. Patients diagnosed with advanced/recurrent EC between Jan 1, 2013, and Dec 31, 2018, were included, with data follow-up until Sept 30, 2020. Eligibility was restricted to patients treated with PBD therapy for advanced/recurrent EC. Demographics, baseline characteristics, and treatments received were reported descriptively. Overall survival (OS), time to next treatment (TTNT; a proxy for progression-free survival), and time to treatment discontinuation (TTD) were depicted using Kaplan-Meier methodology. Survival outcomes were measured from the index date (start of 2L therapy).
Results
3415 pts with advanced/recurrent EC who received a 1L PBD were identified. Among these, 29.3% (n=999) received 2L therapy during the study period. Patient demographics for the post-PBD population are in the table. Median OS was 10.3 mo (95%CI, 9.2–11.1 mo), median TTNT was 7.7 mo (95%CI, 7.1–8.2 mo), and median TTD was 3.4 mo (95%CI, 3.2–3.4 mo).
Conclusions
This study provides RW data from England on the patient population, treatment landscape, and survival outcomes of patients with advanced/recurrent EC that progressed on or after a PBD, showing a median survival of <12 months. Thus, there is a critical unmet need for more effective treatments in this population.